<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Multiplicative Susceptibility: Internal-Dose × Host-Defense × Tissue-Context - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-13</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-13</p>
                <p><strong>Name:</strong> Multiplicative Susceptibility: Internal-Dose × Host-Defense × Tissue-Context</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of why only some cigarette smokers develop lung cancer while others do not, despite smoking being a strong risk factor, based on the following results.</p>
                <p><strong>Description:</strong> Only a subset of smokers develop lung cancer because smoking is necessary but not sufficient: progression requires (i) sufficiently high *internal* delivered/activated carcinogen dose (not captured fully by cigarettes/day or pack-years), (ii) inadequate host defenses that normally eliminate or repair damaged cells (metabolic detoxification, DNA repair, apoptosis, immune surveillance), and (iii) permissive lung tissue context (chronic inflammation/structural lung disease) that increases epithelial turnover and clonal selection. These components combine approximately multiplicatively (or at least super-additively), producing strong inter-individual variability even at similar self-reported smoking histories.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5.2-2025-12-11</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Internal-dose, not just external dose, drives heterogeneity</h3>
            <p><strong>Statement:</strong> Among cigarette smokers, variation in lung-cancer risk at the same reported smoking intensity/duration is partly explained by differences in internal dose and deposition (inhalation topography, compensation, filter effects) and by co-exposures (PM2.5, radon, asbestos, diesel/occupational carcinogens), which add genotoxic burden beyond pack-years and can shift where in the lung carcinogenesis occurs.</p>
            <p><strong>Domain/Scope:</strong> Applies to active cigarette smokers and former smokers in population and occupational settings; relevant across NSCLC and SCLC, with particularly strong implications for adenocarcinoma location (peripheral deposition).</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Machine-measured tar/nicotine yields can misrepresent true internal dose due to smoker compensation.</li>
                <li>If exposure is dominated by non-cigarette sources (e.g., coal/biomass smoke), pack-years alone is an incomplete exposure surrogate.</li>
                <li>Precise quantification requires biomarkers (e.g., cotinine/urinary metabolites/DNA adducts) that are often unavailable.</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Reviews emphasize that inter-individual differences in smoking intensity/duration and inhalation/topography and compensation influence internal carcinogen dose and risk; heavy smokers can reach cumulative lung-cancer risk up to ~30%. <a href="../results/extraction-result-116.html#e116.6" class="evidence-link">[e116.6]</a> <a href="../results/extraction-result-116.html#e116.2" class="evidence-link">[e116.2]</a> <a href="../results/extraction-result-89.html#e89.10" class="evidence-link">[e89.10]</a> <a href="../results/extraction-result-89.html#e89.0" class="evidence-link">[e89.0]</a> <a href="../results/extraction-result-85.html#e85.0" class="evidence-link">[e85.0]</a> </li>
    <li>Biomarkers of exposure/internal dose are explicitly discussed as key to explaining variability: serum cotinine, urinary carcinogen metabolites, and DNA adducts reflect internal dose; DNA adduct levels are proposed to link to susceptibility. <a href="../results/extraction-result-116.html#e116.2" class="evidence-link">[e116.2]</a> <a href="../results/extraction-result-87.html#e87.6" class="evidence-link">[e87.6]</a> </li>
    <li>Ambient air pollution (PM2.5) is a Group 1 carcinogen and associated with ~8–19% increased lung-cancer mortality per 10 μg/m3; additional environmental/occupational exposures (asbestos, silica, diesel, radon) add to risk and explain heterogeneity among smokers. <a href="../results/extraction-result-116.html#e116.6" class="evidence-link">[e116.6]</a> <a href="../results/extraction-result-85.html#e85.3" class="evidence-link">[e85.3]</a> <a href="../results/extraction-result-89.html#e89.5" class="evidence-link">[e89.5]</a> <a href="../results/extraction-result-88.html#e88.8" class="evidence-link">[e88.8]</a> <a href="../results/extraction-result-89.html#e89.4" class="evidence-link">[e89.4]</a> <a href="../results/extraction-result-89.html#e89.3" class="evidence-link">[e89.3]</a> <a href="../results/extraction-result-116.html#e116.6" class="evidence-link">[e116.6]</a> </li>
    <li>Coal/biomass smoke exposures show elevated lung-cancer odds (e.g., coal OR 1.64 overall; OR 4.93 in Asia), implying substantial non-cigarette carcinogen contributions that can confound smoker-only comparisons. <a href="../results/extraction-result-116.html#e116.6" class="evidence-link">[e116.6]</a> <a href="../results/extraction-result-116.html#e116.6" class="evidence-link">[e116.6]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
        <p><strong>Explanation:</strong> Core components are established; novelty is the integrated, testable decomposition of heterogeneity into internal-dose and co-exposure terms as first-class determinants rather than residual noise.</p>            <p><strong>What Already Exists:</strong> Dose-response for smoking and the role of co-exposures (air pollution, radon, asbestos) are well established, as is the concept that internal-dose biomarkers improve exposure assessment.</p>            <p><strong>What is Novel:</strong> The explicit framing that internal-dose heterogeneity is a primary driver of 'who among similar smokers gets cancer' and that deposition/topography plus co-exposure can shift anatomic/histologic pathways is a synthesis that motivates mediation-style testing beyond pack-years.</p>
        <p><strong>References:</strong> <ul>
    <li>Spitz et al. (2011) Lung cancer: epidemiology, etiology, and prevention [dose metrics, internal-dose biomarkers, co-exposures as modifiers]</li>
    <li>Pope et al. (2002) Lung cancer, cardiopulmonary mortality, and long-term exposure to fine particulate air pollution [PM2.5 risk estimates, environmental dose contribution]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Host-defense capacity modulates conversion of dose to cancer</h3>
            <p><strong>Statement:</strong> For a given internal carcinogen dose, smokers with reduced detoxification capacity and/or reduced DNA repair capacity (or higher mutagen sensitivity) have higher probability of accumulating and fixing driver mutations, increasing lung-cancer risk beyond what pack-years predict.</p>
            <p><strong>Domain/Scope:</strong> Applies to smokers and ex-smokers; strongest where tobacco carcinogens that form DNA adducts dominate (PAHs/NNK) and where host variation in phase I/II metabolism and DNA repair is present.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Candidate-gene effects can be modest and heterogeneous across studies due to exposure misclassification and population differences.</li>
                <li>Some DNA repair gene associations are inconsistent; phenotypic repair assays can be affected by timing (post-diagnosis) and lab variability.</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Metabolic gene variation (e.g., GSTM1 null) increases lung-cancer odds, with stronger effect in smokers (GSTM1 null OR 1.34 in smokers vs 1.20 in non-smokers in Chinese meta-analysis), consistent with detoxification modifying the effect of smoking exposure. <a href="../results/extraction-result-79.html#e79.0" class="evidence-link">[e79.0]</a> </li>
    <li>Review describes inter-individual susceptibility as depending on activation/detoxification gene–enzyme interactions and DNA adduct formation (conceptual). <a href="../results/extraction-result-87.html#e87.6" class="evidence-link">[e87.6]</a> <a href="../results/extraction-result-116.html#e116.2" class="evidence-link">[e116.2]</a> </li>
    <li>Reduced DNA repair capacity / mutagen sensitivity phenotypes (and polymorphisms in repair genes) are summarized as increasing lung-cancer risk and showing greater combined risk with smoking than either factor alone (Spitz et al. cited in review). <a href="../results/extraction-result-116.html#e116.3" class="evidence-link">[e116.3]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
        <p><strong>Explanation:</strong> Mechanistic linkage is a synthesis; underlying associations are established but variably replicated.</p>            <p><strong>What Already Exists:</strong> Metabolism and DNA repair variation modifying smoking-associated risk is a long-standing framework (candidate genes, mutagen sensitivity studies).</p>            <p><strong>What is Novel:</strong> Here it is positioned as a conversion-function from internal dose to fixed mutational burden, aligning germline metabolism/repair variation with tumor-genomic endpoints (driver acquisition/TMB) as a mechanistic bridge.</p>
        <p><strong>References:</strong> <ul>
    <li>Chen (2014) The Associations between Two Vital GSTs Genetic Polymorphisms and Lung Cancer Risk in the Chinese Population [phase II detoxification modifiers, smoker amplification]</li>
    <li>Spitz et al. (2011) Lung cancer: epidemiology, etiology, and prevention [DNA repair capacity/mutagen sensitivity framework]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: Inflammatory/structural lung disease creates a permissive tissue context</h3>
            <p><strong>Statement:</strong> Among smokers, chronic inflammatory/structural lung diseases (especially COPD and pulmonary fibrosis) markedly increase lung-cancer risk independent of smoking history, by increasing epithelial injury/repair cycles, field cancerization, and clonal selection of damaged cells.</p>
            <p><strong>Domain/Scope:</strong> Applies primarily to current/former smokers with spirometry-defined COPD or clinically defined fibrotic lung disease; relevant for incident lung cancer risk and not only prognosis.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Potential reverse causation or measurement bias if lung cancer affects spirometry; residual confounding by smoking intensity remains possible.</li>
                <li>Different chronic lung diseases may have different strengths of association and mechanisms.</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Review reports COPD prevalent in 40–70% of lung-cancer patients; one cited study found 50% had spirometric COPD and OR 11.6 for lung cancer independent of age/gender/smoking; COPD in smokers reported ~5-fold increased risk in another review; idiopathic pulmonary fibrosis OR 8.25 after smoking adjustment; α1-antitrypsin carrier status ~2-fold increased risk. <a href="../results/extraction-result-116.html#e116.5" class="evidence-link">[e116.5]</a> <a href="../results/extraction-result-85.html#e85.2" class="evidence-link">[e85.2]</a> </li>
    <li>BLCS semi-competing risk analysis includes COPD as a covariate and reports increased progression hazard in one method (Xu progression log-HR 0.33 ≈ HR 1.39), consistent with a clinically meaningful modifier (though estimates vary by method). <a href="../results/extraction-result-80.html#e80.0" class="evidence-link">[e80.0]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
        <p><strong>Explanation:</strong> Concept is established; novelty is the structured decomposition and emphasis on context as a third multiplicative axis.</p>            <p><strong>What Already Exists:</strong> COPD and pulmonary fibrosis as strong risk factors for lung cancer are well known; inflammation as a mechanistic contributor is widely discussed.</p>            <p><strong>What is Novel:</strong> The explicit role of 'tissue-context permissivity' as a separable axis (distinct from dose and host-defense capacity) provides a structured explanation for large risk gradients among smokers and motivates integrating spirometry/inflammatory biomarkers into risk stratification.</p>
        <p><strong>References:</strong> <ul>
    <li>Spitz et al. (2011) Lung cancer: epidemiology, etiology, and prevention [COPD/fibrosis risk estimates and mechanistic discussion]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 3: Latent susceptibility subgroups remain after measuring major covariates</h3>
            <p><strong>Statement:</strong> Even after accounting for smoking status/pack-years, age, sex, stage, and some clinical factors, there exists substantial residual subject-level heterogeneity (frailty) indicating unmeasured biological or exposure determinants that segregate smokers into high- and low-susceptibility subgroups.</p>
            <p><strong>Domain/Scope:</strong> Applies to NSCLC patient cohorts where semi-competing outcomes (progression and death) are modeled with frailty; this is evidence about heterogeneity among those who developed cancer and may generalize to pre-diagnostic susceptibility heterogeneity.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Frailty estimates depend on model specification and assumptions (e.g., gamma frailty); effect directions for some covariates vary by method in the BLCS analysis.</li>
                <li>Because the cohort includes only cancer patients, frailty reflects heterogeneity in disease course and possibly in etiologic pathways, not direct incidence risk.</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>BLCS neural EM illness–death model reports sizable frailty variance θ = 2.09 (Kendall’s τ ≈ 0.511), indicating substantial unexplained heterogeneity beyond observed predictors; authors also report nonlinear age×sex×smoking interactions. <a href="../results/extraction-result-80.html#e80.0" class="evidence-link">[e80.0]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> Frailty is not new; its use here as a mechanistic pointer to missing susceptibility variables is a synthesis.</p>            <p><strong>What Already Exists:</strong> Unobserved heterogeneity and frailty are established concepts in survival analysis; heterogeneity in lung cancer etiology is widely recognized.</p>            <p><strong>What is Novel:</strong> Using large-scale semi-competing risk frailty plus nonlinear interaction surfaces as empirical evidence for latent susceptibility strata provides a concrete modeling target for integrating omitted biology (e.g., internal-dose biomarkers, repair phenotypes).</p>
        <p><strong>References:</strong> <ul>
    <li>Yang et al. (2022) Deep Learning of Semi-Competing Risk Data via a New Neural Expectation-Maximization Algorithm [frailty variance, nonlinear interactions in BLCS NSCLC cohort]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>In cohorts of smokers matched on pack-years, adding (a) COPD spirometry metrics and (b) internal-dose biomarkers (e.g., urinary carcinogen metabolites/DNA adduct proxies) will significantly improve risk stratification compared with pack-years alone.</li>
                <li>Joint exposure indices (smoking + PM2.5 or smoking + occupational carcinogens) will better explain between-smoker risk variability than smoking metrics alone, particularly in urban/occupationally exposed subgroups.</li>
                <li>Smokers with COPD will show higher prevalence of airway 'field of injury' molecular alterations (e.g., methylation/expression perturbations) than smokers without COPD at similar smoking histories, consistent with a permissive tissue context.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>A three-axis model (internal-dose biomarkers × DNA repair capacity phenotype × COPD/inflammation markers) will identify a small subgroup of smokers with extremely high absolute lifetime risk approaching the upper range (~30%) even at moderate pack-years, while identifying a low-susceptibility subgroup with substantially lower risk at high pack-years.</li>
                <li>Prospective measurement of DNA repair capacity (pre-diagnosis) plus metabolite/adduct biomarkers will mediate a large fraction of the apparent effect of some metabolism genotypes (e.g., GSTM1 null) on incidence, clarifying causal pathways.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If well-powered prospective studies with accurate biomarker-verified exposure show that internal-dose biomarkers do not explain any additional variance in risk beyond pack-years, the internal-dose heterogeneity claim would be weakened.</li>
                <li>If COPD/fibrosis associations with lung cancer disappear after extremely granular smoking exposure adjustment and lagging (reducing reverse causation), the tissue-context permissivity statement would be challenged.</li>
                <li>If frailty variance collapses toward zero after adding a limited set of plausible omitted variables (e.g., COPD, PM2.5, occupational exposures), then the theory’s claim of major latent susceptibility strata would be weakened.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Distinct germline loci that appear smoking-dose independent (e.g., 5p15.33 TERT/CLPTM1L association across never/ex/current smokers, not mediated by cigarettes/day) are not fully explained by a purely dose/defense/context framework without adding intrinsic genomic-maintenance variation explicitly. <a href="../results/extraction-result-105.html#e105.0" class="evidence-link">[e105.0]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>